Cd19 specific chimeric antigen receptor and uses thereof
JP2020018323A
Engineering production method of chemotherapeutic medicine resistant t cell for immune therapy
CA3105331A1
Canola with high oleic acid
WO2020007593A1
Chimeric antigen receptors (car)-expressing cells and combination treatment for immunotherapy of patients with relapse refractory adverse genetic risk aml
WO2019211796A1
Engineering wheat with increased dietary fiber
WO2019185920A1
Tale-nucleases for allele-specific codon modification
EP3694546A1
Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen
CA3086267A1
Method for improving production of car t cells
WO2019129850A1
Off-the-shelf engineered cells for therapy
WO2019106163A1
Reprogramming of genetically engineered primary immune cells
JP2019047801A
Methods for engineering T cells for immunotherapy by using RNA-guided CAS nuclease system
HK1253706A1
Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
WO2019072824A1
Improved anti-cd123 car in universal engineered immune t cells
WO2019020733A1
Methods of antigen-dependent chimeric antigen receptor (car) immune cell selection
US2020216515A1
Methods of antigen-dependent chimeric antigen receptor (car) immune cell selection
EP3638260A1
Engineered immune cells resistant to tumor microoenvironment
WO2019016360A1
Engineered immune cells resistant to tumor microoenvironment
EP3645036A1
Cellular immunotherapy for repetitive administration
WO2018234239A1
Anti-hbv combination therapies involving specific endonucleases
WO2018206791A1
Protease based switch chimeric antigen receptors for safer cell immunotherapy
